Table 2.
Comparing demographic and laboratory data between COV and COV-HD patients
| COV group (n = 30) | COV-HD group (n = 30) | P Value | |
|---|---|---|---|
| Demographic and Clinical data | |||
| Age | 60.6 (13.6) | 54 (8.9) | 0.115 a |
| Gender | |||
| Male | 9 (30) | 21 (70) | 0.006 |
| Female | 21 (70) | 9 (30) | |
| Diabetes | 14 (46.7) | 13 (43) | 0.5 |
| Number of days of hospital admission | 15 (3–33) | 3 (0–12) | 0.001 a |
| O2 Saturation at admission | 88 (60–99) | 89 (72–96) | 0.008 a |
| Place of stay (OPC, Ward, ICU) | |||
| OPC | 2 (6.7) | 12 (40) | 0.009c |
| Ward | 14 (46.7) | 10 (33.5) | |
| ICU | 14 (46.7) | 8 (26.5) | |
| Outcome | |||
| OPC | 1 (3.3) | 11 (36.5) | 0.005c |
| Discharge | 16 (53.3) | 12 (40) | |
| Death | 13 (43.3) | 7 (23.5%) | |
| Radiological Data | |||
| GGO percentage% | 50 (0–86) | 45 (0–69) | 0.19 a |
| Total severity score in CT (TSS) (out of 20) | 7.5 (2–15) | 7 (2–15) | 0.12 a |
| TSS (Severe > 7.5) | 16 (53%) | 10 (33%) | 0.08 a |
| Laboratory data | |||
| CBC and Coagulation | |||
| Hemoglobin (mg/dl) | 11.25 (6.5–17.6) | 9.5 (7.8–12.7) | < 0.001 a |
| Total WBCs (cell/ μl) | 8616 (3200–20,800) | 7300 (3560–22,500) | 0.423a |
| Neutrophil (cell/ μl) | 6790 (2080–14,890) | 4346 (2242–18,225) | 0.152 a |
| Lymphocyte (cell/ μl) | 1100 (500–3600) | 1204 (480–5000) | 0.9 a |
| NL ratio | 5.6 (1.81–13.22) | 2.8 (1.84–21.75) | 0.132 a |
| D-dimer (ng/ml) | |||
| Less than 200 | 19 (63.3%) | 13 (43.3) | 0.04 a |
| 200–500 | 8 (26.7%) | 4 (13.3) | |
| More than 500 | 3 (10%) | 13 (43.3) | |
| Flowcytometry Data | |||
| CD4+ T cells (cell/ μl) | 33.8 (2.2–359.1) | 52.16 (1.92–399.6) | 0.4 a |
| Tregs (cell/ μl) | 0.011 (0–0.33) | 0.028 (0–5.77) | 0.1 a |
| CD39 expressing Tregs (cell/ μl) | 0.002 (0–0.14) | 0.006 (0–5.6) | 0.04 a |
Non-parametric data: Median (25–75%)
Nominal data: Number (Percentage)
a Mann-Whitney U test
C chi square test